Molecular subsets in the gene expression signatures of scleroderma skin

PLoS ONE

Volumn 3, Issue 7, 2008, Pages

  Milano, Ausra ^a,d   Pendergrass, Sarah A ^a   Sargent, Jennifer L ^a   George, Lacy K ^a   McCalmont, Timothy H ^c   Connolly, M Kari ^b   Whitfield, Michael L ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Optigen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; DIFFUSE SCLERODERMA; DISEASE DURATION; DISEASE SEVERITY; DNA HYBRIDIZATION; DNA MICROARRAY; FEMALE; FOREARM; GASTROINTESTINAL DISEASE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MAPPING; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; INTERSTITIAL LUNG DISEASE; MALE; RAYNAUD PHENOMENON; SCLERODERMA; SCORING SYSTEM; SKIN BIOPSY; SKIN ULCER; SYSTEMIC SCLEROSIS; BIOPSY; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; GENETICS; LIMITED SCLERODERMA; METABOLISM; MIDDLE AGED; PHENOTYPE;

ADULT; AGED; BIOPSY; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; SCLERODERMA, DIFFUSE; SCLERODERMA, LIMITED; SCLERODERMA, SYSTEMIC;

EID: 49949114547     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002696     Document Type: Article

References (86)

1. Mayes MD (1998) Classification and epidemiolofy of scleroderma. Semin Cutan Med Surg 17: 22-26.
2. Mayes MD, Lacey JV Jr., Beebe-Dimmer J, Gillespie BW, Cooper B, et al. (2003) Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 48: 2246-2255.
3. Leroy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, et al. (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. JRheumatol 15: 202-205.
4. Medsger TA (2001) Systemic sclerosis (scleroderma): clinical aspects. In: Koopman WJ, ed. Arthritis and Allied Conditions. 14th ed. Philadelphia: Lippincott Williams & Wilkins. 1590 p.
5. Masi AT (1988) Classification of systemic sclerosis (scleroderma): relationship of cutaneous subgroups in early disease to outcome and serologic reactivity. J Rheumatol 15: 894-898.
6. Perera A, Fertig N, Lucas M, Rodriguez-Reyna TS, Hu P, et al. (2007) Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum 56: 2740-2746.
7. Steen VD, Medsger TA Jr. (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43: 2437-2444.
8. Committee. SISCotARADaTC (1980) Preliminary criteria for the classification of systemic sclerosis (sclerciderma). 23: 581-590.
9. Scibold JR, McCloskey DA (1997) Skin involvement as a relevant outcome measure in clinical trials of systemic sclerosis. Curr Opin Rheumatol 9: 571-575.
10. Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, et al. (2000) Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 43: 2445-2454.
11. Clements PJ, Lachenbruch PA, Ng SC, Simmons M, Sterz M, et al. (1990) Skin Score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 33: 1256-1263.
12. Barnett AJ, Miller MH, Littljohn GO (1988) A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease. J Rheumatol 15: 276-283.
13. Scussel-Lonzetti L, Joyal F, Raynauld JP, Roussin A, Rich E, et al. (2002) Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. 81: 154-167.
14. Shand L, Lunt M, Nihtyanova S, Hoseini M, Silman A, et al. (2007) Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum 56: 2422-2431.
15. Steen VD, Medsger TA Jr. (2001) Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum 44: 2828-2835.
16. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, et al. (2003) Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Nad Acad Sci U S A 100: 12319-12324.
17. Gardner H, Shearstone JR, Bandaru R, Crowell T, Lynes M, et al. (2006) Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explained fibroblasts. Arthritis Rheum 54: 1961-1973.
18. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95: 14863-14868.
19. Sakkas LJ, Xu B, Artlett CM, Lu S, Jimenez SA, et al. (2002) Oligoclonal T cell expansion in the skin or patients with systemic sclerosis. J Immunol 168: 3649-3659.
20. Kraling BM, Juhasz I, Freundlich B, Maul GG, Jimenez SA (1996) Transplantation of systemic sclerosis (SSc) skin grafts into severe combined immunodeficient mice: increased presence of SSc leukocytes in SSc skin grafts and autoantibody production following autologous leukocyte transfer. Pathobiology 64: 99-114.
21. Kraling BM, Maul GG, Jimenez SA (1995) Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiology 63: 48-56.
22. Yurovsky VV, Sutton PA, Schulze DH, Wigley FM, Wise RA, et al. (1994) Expansion of selected V delta 1+ gamma delta T cells in systemic sclerosis patients. J Immunol 153: 881-891.
23. Fleischmajer R, Perlish JS, Reeves JR (1977) Cellular infiltrates in scleroderma skin. 20: 975-984.
24. Trowbridge IS, Thomas ML (1994) CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. Annu Rev Immunol 12: 85-116.
25. Trowbridge IS, Ostergaard HL, Johnson P (1991) CD45: a leukocyte-specific member of the protein tyrosine phosphatase family. Biochim Biophys Acta 1095: 46-56.
26. Koretzky GA, PicusJ, Thomas ML, Weiss A (1990) Tyrosine phosphatase CD45 is essential for coupling T-cell antigen receptor to the phosphatidyl inositol pathway. Nature(London) 346: 66-68.
27. Sewell WA, Brown MH, Clipstone NA, Crumpton MJ (1989) The T lymphocyte CD2 antigen-genetic and functional studies. Transplant Proc 21: 41-43.
28. Sewell WA, Brown MH, Dunne J, Owen MJ, Crumpton MJ (1986) Molecular cloning of the human T-lymphocyte surface CD2 (T11) antigen. Proc Natl Acad Sci U S A 83: 8718-8722.
29. Hale G, Xia MQ, Tighe HP, Dyer MJ, Waldmann H (1990) The CAMPATH-1 antigen (CDw52). Tissue Antigens 35: 118-127.
30. LedbetterJA, Evans RL, Lipinski M, Cunningham-Rundles C, Good RA, et al. (1981) Evolutionary conservation of surface molecules that distinguish T lymphocyte helper/inducer and cytotoxic/suppressor subpopulations in mouse and man. J Exp Med 153: 310-323
31. Sayers TJ, Lloyd AR, McVicar DW, O'Connor MD, Kelly JM, et al. (1996) Cloning and expression of a second human natural killer cell granule tryptase, HNK-Tryp-2/granzyme 3. J Leukoc Biol 59: 763-768.
32. Przetak MM, Yoast S, Schmidt BF (1995) Cloning of cDNA for human granzyme 3. FEBS Lett 364: 268-271.
33. Smyth MJ, Hulett MD, Thia KY, Young HA, Sayers TJ, et al. (1995) Cloning and characterization of a novel NK cell-specific serine protease gene and its functional 5′-flanking sequences. Immunogenetics 42: 101-111.
34. Baker E, Sayers TJ, Sutherland GR, Smyth MJ (1994) The genes encoding NK cell granule serine proteases, human tryptase-2 (TRYP2) and human granzyme A (HFSP), both map to chromosome 5q11-q12 and define a new locus for cytotoxic lymphocyte granule tryptases. Immunogenetics 40: 235-237.
35. Yoshida R, Imai T, Hieshima K, Kusuda J, Baba M, et al. (1997) Molecular cloning of a novel human CC chemokine EBI1-ligand chemokine that is a specific functional ligand for EBI1, CCR7. J Biol Chem 272: 13803-13809.
36. Jensen PE, Weber DA, Thayer WP, Chen Y, Dao CT (1999) HLA-DM and the MHC class II antigen presentation pathway. Immunol Res 20: 195-205.
37. Jensen PE, Weber DA, Thayer WP, Westerman LE, Dao CT (1999) Peptide exchange in MHC molecules. Immunol Rev 172: 229-238.
38. Cresswell P (1994) Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol 12: 259-293.
39. Gore Y, Starlets D, Maharshak N, Becker-Herman S, Kaneyuki U, et al. (2007) Macrophage migration inhibitory factor (MIF) induces B cell survival by activation of a CD74/CD44 receptor complex. J Biol Chem.
40. Lantner F, Starlets D, Gore Y, Flaishon L, Yamit-Hezi A, et al. (2007) CD74 induces TAp63 expression leading to B-cell survival. Blood 110: 4303-4311.
41. Wagtmann N, Rojo S, Eichler E, Mohrenweiser H, Long EO (1997) A new human gene complex encoding the killer cell inhibitory receptors and related monocyte/macrophage receptors. Curr Biol 7: 615-618.
42. Arm JP, Nwankwo C, Austen KF (1997) Molecular identification of a novel family of human Ig superfamily members that possess immunoreceptor tyrosine-based inhibition motifs and homology to the mouse gp49B1 inhibitory receptor. J Immunol 159: 2342-2349.
43. Sulahian TH, Hogger P, Wahner AE, Wardwell K, Goulding NJ, et al. (2000) Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine 12: 1312-1321.
44. LeClair RJ, Durmus T, Wang Q, Pyagay P, Terzic A, et al. (2007) Cthrcl is a novel inhibitor of transforming growth factor-beta signaling and neointimal lesion formation. Circ Res 100: 826-833.
45. Pyagay P, Heroult M, Wang Q, Lehnert W, Belden J, et al. (2005) Collagen triple helix repeat containing 1, a novel secreted protein in injured and diseased arteries, inhibits collagen expression and promotes cell migration. Circ Res 96: 261-268.
46. Whitfield ML, George LK, Grant GD, Perou CM (2006) Common markers of proliferation. Nat Rev Cancer 6: 99-106.
47. Perou CM, Sorlie T, Eisen MB, van de RM, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature(London) 406: 747-752.
48. Perou CM, Jeffrey SS, van de RM, Rees CA, Eisen MB, et al. (1999) Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A 96: 9212-9217.
49. Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, et al. (2002) Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 13: 1977-2000.
50. Fleischmajer R, Perlish JS (1977) [3H]Thymidine labeling of dermal endothelial cells in scleroderma. J Invest Dermatol 69: 379-382.
51. Kazandjian S, Fiessinger JN, Camilleri JP, Dadoune JP, Housset E (1982) Endothelial cell renewal in skin of patients with progressive systemic sclerosis (PSS): an in vitro autoradiographic study. Acta Derm Venereol 62: 425-429.
52. Rajkumar VS, Howell K, Csiszar K, Denton CP, Black CM, et al. (2005) Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther 7: R1113-1123.
53. Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, et al. (2000) Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 131: 1262-1274.
54. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, et al. (1999) Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401: 282-286.
55. Grieco P, Carotenuto A, Campiglia P, Marinelli L, Lama T, et al. (2005) Urotensin-II receptor ligands. From agonist to antagonist activity. J Med Chem 48: 7290-7297.
56. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
57. Liu Y, Hayes DN, Nobel A, Marron JS (2007) Statistical Significance of Clustering for High Dimension Low Sample Size Data. Journal of the American Statistical Association Submitted.
58. Monti S, Tamayo P, Mesirov JP, Golub TR (2003) Consensus Clustering: A resampling-based method for class discovery and visualization of gene expression microarray data. Machine Learning 52: 91-118.
59. Raychaudhuri S, Stuart JM, Altman RB (2000) Principal components analysis to summarize microarray experiments: application to sporulation time series. Pac Symp Biocomput. pp 455-466.
60. Margolin AA, Greshock J, Naylor TL, Mosse Y, Maris JM, et al. (2005) CGHAnalyzer: a stand-alone software package for cancer genome analysis using array-based DNA copy number data. Bioinformatics 21: 3308-3311.
61. Segal E, Friedman N, Koller D, Regev A (2004) A module map showing conditional activity of expression modules in cancer. Nat Genet 36: 1090-1098.
62. Stuart JM, segal E, Koller D, Kim SK (2003) A Gene-Coexpression Network for Global Discovery of Conserved Genetic Modules. 392: 249-255.
63. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. 25: 25-29.
64. Palmer C, Diehn M, Alizadeh AA, Brown PO (2006) Cell-type specific gene expression profiles of leukocytes in human peripheral blood. BMC Genomics 7: 115.
65. Funk CD (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294: 1871-1875.
66. Crofford LJ, Wilder RL, Ristimaki AP, Sano H, Remmers EF, et al. (1994) Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J Clin Invest 93: 1095-1101.
67. Kojima F, Naraba H, Sasaki Y, Beppu M, Aoki H, et al. (2003) Prostaglandin E2 is an enhancer of interleukin-1beta-induced expression of membrane-associated prostaglandin E synthase in rheumatoid synovial fibroblasts. Arthritis Rheum 48: 2819-2828.
68. Westman M, Korotkova M, af Klint E, Stark A, Audoly LP, et al. (2004) Expression of microsomal prostaglandin E synthase 1 in rheumatoid arthritis synovium. Arthritis Rheum 50: 1774-1780.
69. Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtmann TS, et al. (2003) Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci U S A 100: 9044-9049.
70. Sheibanie AF, Khayrullina T, Safadi FF, Ganea D (2007) Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis. Arthritis Rheum 56: 2608-2619.
71. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, et al. (2000) Systematic variation in gene expression patterns in human cancer cell lines. nat Genet 24: 227-235.
72. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116-5121.
73. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, et al. (2000) Distinct Types of Diffuse Large B-Cell Lymphoma Identified by Gene Expression Profiling. Nature(London) 403: 503-511.
74. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100: 8418-8423.
75. Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, et al. (2001) Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A 98: 13784-13789.
76. Segal E, Sirlin CB, Ooi C, Adler AS, Gollub J, et al. (2007) Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 25: 675-680.
77. Diehn M, Nardini C, Wang DS, McGovern S, Jayaraman M, et al. (2008) Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc Natl Acad Sci U S A 105: 5213-5218.
78. Meighan-Mantha RL, Hsu DK, Goo Y, Brown SA, Feng SL, et al. (1999) The mitogen-inducible Fn14 gene encodes a type 1 transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem 274: 33166-33176.
79. Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, et al. (2001) A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 15: 837-846.
80. Chicheportiche Y, Chicheportiche R, Sizing I, Thompson J, Benjamin CB, et al. (2002) Proinflammatory activity of TWEAK on human dermal fibroblasts and synoviocytes: blocking and enhancing effects of anti-TWEAK monoclonal antibodies. Arthritis Res 4: 126-133.
81. Novoradovskaya N, Whitfield ML, Basehore LS, Novoradovsky A, Pesich R, et al. (2004) Universal Reference RNA as a standard for microarray experiments. BMC Genomics 5: 20.
82. Saldanha AJ (2004) Java Treeview-extensible visualization of microarray data. Bioinformatics 20: 3246-3248.
83. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, et al. (2006) GenePattern 2.0. Nat Genet 38: 500-501.
84. Pruitt KD, Maglott DR (2001) RefSeq and LocusLink. NCBI gene-centered resources. Nucleic Acids Research 29: 137-140.
85. Heid CA, Stevens J, Livak KJ, Williams PM (1996) Real time quantitative PCR. 6: 986-994.
86. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) Method. Methods 25: 402-408.